Reduction by Niceritrol Treatment of Serum Lipoprotein(a) in Normolipidemic Patients with Coronary Artery Disease.
Year: 1993
Type: article
Study design: Clinical Trial
Abstract: SANO, R., FUJINO, A., SAITO, T., TAKENAKA, K., YAHATA, K., OGYU, A. and TOYOTA, T. Reduction by Niceritrol Treatment of Serum Lipoprotein(a) in Normolipidemic Patients with Coronary Artery Disease. Tohoku J. Exp. Med., 1993, 169 (4), 299-307-The effect of niceritrol at an ordinary dose (1500mg/ day) on the serum lipoprotein(a) (Lp(a)) concentration was investigated in 25 normolipidemic patients with coronary artery disease. The serum Lp(a) level was reduced by approximately 21% after 3 months of treatment (before treatment, 30.3±4.1mg/100ml; during treatment, 22.6±2.4mg/100ml; p<0.01). By one month after the drug was discontinued, the Lp(a) returned to a pretreatment level (30.8±2.8mg/100ml). The levels of LDL-cholesterol and apoB were decreased significantly by the drug therapy; LDL-cholesterol increased closely to a pretreatment level after withdrawal of the drug. The percentage reduction of Lp(a) was significantly correlated with that of fibrinogen (r=0.763, p<0.01). Plasma concentration of fibrinogen was decreased in the patients whose reduction rate of Lp(a) was 30% or more. These results indicate that niceritrol has Lp(a)-lowering effect; sufficient reduction of Lp(a) may improve dyscoagulopathy of patients with coronary artery disease.-coronary artery disease; normolipidemia; lipoprotein(a); plasminogen activator inhibitor-1; fibrinogen; Niceritrol
DOI: 10.1620/tjem.169.299
Authors: RYUICHI SANO, AKIHISA FUJINO, TSUNEYOSHI SAITO, KEIJI TAKENAKA, YOSHIKAZU YAHATA, AKINORI OGYU, TAKAYOSHI TOYOTA
Institutions: Yonezawa City Hospital, Tohoku University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2007203008